Evidence map›Paper›PMID 28538556›Full record

Trial reportPlastic and reconstructive surgery2017

A Randomized, Controlled, Multicenter Study of Juvéderm Voluma for Enhancement of Malar Volume in Chinese Subjects.

Dong Li, Xiaojun Wang, Yan Wu, Jiaming Sun, Qin Li, Shuzhong Guo, Yi Jia, Diane K Murphy

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Plastic and reconstructive surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Hyaluronic Acid ProfhiloMedicina (Kaunas, Lithuania) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Expert Consensus on Hyaluronic Acid Filler Facial Injection for Chinese Patients.Plastic and reconstructive surgery. Global open · 2020
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dong LiBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Xiaojun WangBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Yan WuBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Jiaming SunBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Qin LiBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Shuzhong GuoBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Yi JiaBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.
Diane K MurphyBeijing, Hubei Province, and Guang Dong Province, People's Republic of China; and Irvine, Calif.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyaluronic acid gels are used to restore volume to the midface, but there are few data published on this use in Asian subjects.

methodsThis study evaluated the safety and effectiveness in Chinese subjects of Juvéderm Voluma, a 20-mg/ml hyaluronic acid gel formulated for midface volumizing. This prospective, multicenter study randomized 119 subjects aged 18 years or older to a treatment group and 27 subjects to a no-treatment control group. The primary effectiveness endpoint was the objectively measured magnitude of change from baseline in volume of the midface area (right and left combined) calculated by digital analysis at month 6 using three-dimensional images for all subjects in both groups. Effectiveness was protocol-defined as a mean change for the treatment group that was significantly greater than that for the control group at month 6 using a one-side two-group t test performed at the 5 percent level.

resultsWith a median volume of 2 ml of Voluma injected, the primary effectiveness endpoint was met, with the mean change from baseline to 6 months in malar volume for the treatment group (1.83 ml) being significantly greater than that for the control group (0.11 ml; p < 0.001). The secondary effectiveness endpoints of responder rate (malar volumization rated improved or much improved) using the Global Aesthetic Improvement Scale as assessed at month 6 by the investigator and by the subject were 98.2 and 93.8 percent, respectively. The most common treatment-related adverse events were mild injection-site swelling and bruising.

conclusionJuvéderm Voluma is effective and well tolerated for midface augmentation in Chinese subjects. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

Indexed as

CheekCosmetic TechniquesAdultAsian PeopleChinaEstheticsFemaleHumansHyaluronic AcidInjections, SubcutaneousMaleMiddle AgedPatient SafetyPatient SatisfactionProspective StudiesReference ValuesHyaluronic AcidJuvederm VOLUMA

Identifiers

PMID28538556
PMCPMC5444429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.